Biography

Dr. Harry Karmouty-Quintana earned his PhD in 2006 on Experimental Pulmonary Diseases assessed by Magnetic Resonance Imaging, a collaborative program with Novartis Pharma (Switzerland), and King’s College London (UK).

His research program focuses on the translational mechanisms that drive vascular remodeling and fibrosis, integrating discoveries in RNA biology, extracellular matrix remodeling, and aging pathways to identify therapeutic targets in pulmonary hypertension, systemic sclerosis-associated interstitial lung disease, idiopathic pulmonary fibrosis, and post-viral lung disease. By bridging basic molecular insights with clinical samples and preclinical models, his work aims to accelerate the development of novel diagnostics and therapies for patients with life-threatening lung disorders.

Dr. Karmouty-Quintana has received continuous support from the NIH, Department of Defense, American Heart Association, and American Lung Association. In addition to advancing translational research, he has played a leading role in graduate education and institutional program development, including directing the Molecular and Translational Biology Graduate Program and overseeing the lung tissue biorepository to support cross-disciplinary collaborations globally.

Education

PhD
King’s College - London, UK
Post Graduate Training
McGill University, Canada University of Texas Medical School – Houston, TX